S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
S&P 500   4,280.15 (+1.73%)
DOW   33,761.05 (+1.27%)
QQQ   330.39 (+1.95%)
AAPL   172.10 (+2.14%)
MSFT   291.91 (+1.70%)
META   180.50 (+1.70%)
GOOGL   121.68 (+2.39%)
AMZN   143.55 (+2.07%)
TSLA   900.09 (+4.68%)
NVDA   187.09 (+4.27%)
NIO   21.11 (+1.39%)
BABA   94.77 (-0.11%)
AMD   100.83 (+2.76%)
MU   65.04 (+4.36%)
T   18.27 (+1.27%)
CGC   3.30 (+4.76%)
GE   79.93 (+1.31%)
F   16.18 (+2.21%)
DIS   121.57 (+3.30%)
AMC   24.44 (-3.97%)
PYPL   101.10 (+2.01%)
PFE   50.11 (+3.77%)
NFLX   249.30 (+2.72%)
NYSEAMERICAN:CANF

Can-Fite BioPharma - CANF Stock Forecast, Price & News

$0.89
-0.01 (-1.11%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.86
$0.90
50-Day Range
N/A
52-Week Range
$0.78
$2.60
Volume
69,565 shs
Average Volume
342,219 shs
Market Capitalization
$24.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.63

Can-Fite BioPharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
644.4% Upside
$6.63 Price Target
Short Interest
Healthy
2.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.07) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

CANF stock logo

About Can-Fite BioPharma (NYSEAMERICAN:CANF) Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Stock News Headlines

Can-Fite Granted Key NASH Patent in Israel
Can-Fite BioPharma Ltd.(CANF)
See More Headlines
Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Company Calendar

Last Earnings
5/26/2022
Today
8/12/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:CANF
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.63
High Stock Price Forecast
$8.25
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+644.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-12,610,000.00
Net Margins
-1,478.90%
Pretax Margin
-1,478.90%

Debt

Sales & Book Value

Annual Sales
$850,000.00
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$24.20 million
Optionable
Optionable
Beta
1.83

Key Executives

  • Dr. Pnina Fishman Ph.D. (Age 74)
    Scientific Founder, CEO & Director
    Comp: $644k
  • Mr. Motti Farbstein (Age 58)
    Chief Operating & Financial Officer
    Comp: $416k
  • Dr. Sari Fishman Ph.D. (Age 50)
    VP of Bus. Devel.
    Comp: $317k
  • Dr. Ilan Cohn Ph.D. (Age 68)
    Co-Founder & Chairman
  • Dr. Vibeke Strand FACP
    FACR, FACR (USA), M.D., Sr. Clinical Advisor













CANF Stock - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CANF shares.
View CANF analyst ratings
or view top-rated stocks.

What is Can-Fite BioPharma's stock price forecast for 2022?

2 brokers have issued 1-year target prices for Can-Fite BioPharma's shares. Their CANF share price forecasts range from $5.00 to $8.25. On average, they anticipate the company's share price to reach $6.63 in the next twelve months. This suggests a possible upside of 644.4% from the stock's current price.
View analysts price targets for CANF
or view top-rated stocks among Wall Street analysts.

How have CANF shares performed in 2022?

Can-Fite BioPharma's stock was trading at $1.17 at the start of the year. Since then, CANF stock has decreased by 23.9% and is now trading at $0.89.
View the best growth stocks for 2022 here
.

Are investors shorting Can-Fite BioPharma?

Can-Fite BioPharma saw a drop in short interest during the month of July. As of July 31st, there was short interest totaling 586,400 shares, a drop of 10.6% from the July 15th total of 655,700 shares. Based on an average trading volume of 379,600 shares, the short-interest ratio is currently 1.5 days.
View Can-Fite BioPharma's Short Interest
.

How were Can-Fite BioPharma's earnings last quarter?

Can-Fite BioPharma Ltd. (NYSEAMERICAN:CANF) issued its quarterly earnings data on Thursday, May, 26th. The biotechnology company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.12) by $0.03. The biotechnology company earned $0.21 million during the quarter, compared to analyst estimates of $0.20 million. Can-Fite BioPharma had a negative trailing twelve-month return on equity of 145.21% and a negative net margin of 1,478.90%.

What other stocks do shareholders of Can-Fite BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Can-Fite BioPharma investors own include OPKO Health (OPK), Advanced Micro Devices (AMD), BioLineRx (BLRX), Genocea Biosciences (GNCA), Arbutus Biopharma (ABUS), Biocept (BIOC), Pfizer (PFE), Protalix BioTherapeutics (PLX), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

What is Can-Fite BioPharma's stock symbol?

Can-Fite BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CANF."

How do I buy shares of Can-Fite BioPharma?

Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Can-Fite BioPharma's stock price today?

One share of CANF stock can currently be purchased for approximately $0.89.

How much money does Can-Fite BioPharma make?

Can-Fite BioPharma (NYSEAMERICAN:CANF) has a market capitalization of $24.20 million and generates $850,000.00 in revenue each year. The biotechnology company earns $-12,610,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact Can-Fite BioPharma?

Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon P.O. Box 7537, PETAH TIKVA, 49170, Israel. The official website for the company is www.canfite.co.il. The biotechnology company can be reached via phone at (723) 924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378.

This page (NYSEAMERICAN:CANF) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.